This website is best experienced in vertical orientation.
Please rotate your device for optimal display.

Making patient
centricity a reality

An interview with David Meek

“Ipsen’s purpose is clearer than ever: to deliver new and innovative treatments to patients so they can live the life they deserve.”

Read the full interview

2018 Highlights

2018 was a remarkable year for Ipsen. We remain focused on executing our internal and external innovation strategy to build a robust pipeline, ensure continued growth and optimize value for patients and shareholders.

2018 Highlights

2018 was a remarkable year for Ipsen. We remain focused on executing our internal and external innovation strategy to build a robust pipeline, ensure continued growth and optimize value for patients and shareholders.

january 16, 2018

Ipsen and Exelixis announce phase III trial results of cabozantinib…

Read more

march 28, 2018

Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®…

Read more

july 4, 2018

Ipsen announces CELESTIAL phase III pivotal trial results in the New England Journal of Medicine

Read more

september 21, 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

Read more

november 15, 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib

Read more

december 31, 2018

Somatuline® achieved sales of over USD 1 billion…

Read more

APRIL 18, 2019

Ipsen Completes Acquisition of Clementia Pharmaceuticals

Read more

we listen

Patients are at the heart of everything we do. To serve them, we must understand their needs, gain their insights and learn about their hopes for the future. Everything we achieve starts with listening to what they have to say.

Read more

we innovate

Our ambitious goal is to bring new hope to patients. To succeed, we must be bold. That’s why we innovate. Creative, agile and driven, we seek out new solutions for some of the hardest-to-treat conditions, so no patient is left behind.

Read more

we deliver

We promise our patients innovative treatments, a bold vision for the future and new hope. Our outstanding results speak for themselves: we deliver on our promises every day because patients can’t wait.

Read more